Hologic, Inc. $HOLX Shares Acquired by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Hologic, Inc. by 71.5%, owning 10,909 shares valued at approximately $707,000 after acquiring additional shares in the most recent quarter.
• Hologic reported $1.08 EPS for the latest quarter, exceeding analysts' expectations, and projected future guidance of 4.230-4.260 EPS for FY 2025.
• The company’s market capitalization is currently around $15.17 billion, with institutional investors holding 94.73% of its stock.

Wealth Enhancement Advisory Services LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 71.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,909 shares of the medical equipment provider's stock after acquiring an additional 4,548 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Hologic were worth $707,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Procyon Advisors LLC acquired a new position in Hologic during the first quarter worth about $692,000. Clean Yield Group lifted its stake in Hologic by 15.9% in the 1st quarter. Clean Yield Group now owns 52,909 shares of the medical equipment provider's stock worth $3,268,000 after acquiring an additional 7,263 shares in the last quarter. Washington Capital Management Inc. raised its stake in shares of Hologic by 94.8% during the 1st quarter. Washington Capital Management Inc. now owns 15,445 shares of the medical equipment provider's stock worth $954,000 after purchasing an additional 7,515 shares in the last quarter. Wedge Capital Management L L P NC raised its stake in shares of Hologic by 37.0% during the 1st quarter. Wedge Capital Management L L P NC now owns 625,928 shares of the medical equipment provider's stock worth $38,664,000 after purchasing an additional 168,889 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Hologic by 22.3% during the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Trading Up 0.5%

NASDAQ HOLX opened at $68.22 on Friday. The company has a market capitalization of $15.17 billion, a PE ratio of 28.31, a P/E/G ratio of 2.33 and a beta of 0.63. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a 50-day simple moving average of $66.97 and a 200 day simple moving average of $63.08. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of a number of recent analyst reports. Evercore ISI raised their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Argus lifted their price objective on Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Mizuho set a $75.00 price objective on Hologic in a report on Thursday, July 31st. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and boosted their price target for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Hologic in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, Hologic has a consensus rating of "Moderate Buy" and a consensus target price of $79.38.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.